Pilot/Phase IIa Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes

Trial Profile

Pilot/Phase IIa Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Fezolinetant (Primary)
  • Indications Hot flashes
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Ogeda
  • Most Recent Events

    • 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
    • 15 Jan 2017 This trial was completed in Belgium, according to European Clinical Trials Database.
    • 04 Jan 2017 Primary endpoint has been met. (Hot Flash severity at week- 12)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top